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Wollongong, Australia; and kSchool of Chemistry and Physics, University of Adelaide, Adelaide, AustraliaABSTRACT Themolecular chaperone aB-crystallin is a small heat-shock protein that is upregulated in response to a multitude
of stress stimuli, and is found colocalized with Ab amyloid fibrils in the extracellular plaques that are characteristic of Alzheimer’s
disease. We investigated whether this archetypical small heat-shock protein has the ability to interact with Ab fibrils in vitro. We
find that aB-crystallin binds to wild-type Ab42 fibrils with micromolar affinity, and also binds to fibrils formed from the E22G Arctic
mutation of Ab42. Immunoelectron microscopy confirms that binding occurs along the entire length and ends of the fibrils. Inves-
tigations into the effect of aB-crystallin on the seeded growth of Ab fibrils, both in solution and on the surface of a quartz crystal
microbalance biosensor, reveal that the binding of aB-crystallin to seed fibrils strongly inhibits their elongation. Because the lag
phase in sigmoidal fibril assembly kinetics is dominated by elongation and fragmentation rates, the chaperone mechanism iden-
tified here represents a highly effective means to inhibit fibril proliferation. Together with previous observations of aB-crystallin
interaction with a-synuclein and insulin fibrils, the results suggest that this mechanism is a generic means of providing molecular
chaperone protection against amyloid fibril formation.INTRODUCTIONAlzheimer’s disease (AD) is the most common cause of
senile dementia, affecting >26 million people worldwide
(1). This neurodegenerative condition is characterized by
fibrillar protein deposition in both extracellular plaques and
intracellular neurofibrillary tangles within the brain. The
major constituents of the extracellular plaques are amyloid-b
(Ab) peptides, which are 39–43 amino acid residue cleavage
products of the amyloid precursor protein (APP), an integral
membrane protein. The aggregation of these peptides is
thought to be critical to the pathogenesis of the disease (2).
However, other proteins, including small heat-shock proteins
(sHsps), a ubiquitous class of molecular chaperones, are also
found colocalized with Ab peptides in extracellular plaques
(3–7). For example, the most extensively studied sHsp,
aB-crystallin, (referred to as HSPB5 in the recently revised
systematic nomenclature of the sHsps) is present at increased
levels in the temporal and frontal lobes of postmortem AD
brains (3,4), with the majority being localized within astro-
cytes and oligodendrocytes (4,8), and in the neurons
surrounding senile plaques (8,9).
aB-Crystallin is found not only in the brain (10) but also in
many other regions of the human body, including the retina,
heart, skeletal muscle, skin, spinal cord, kidneys, lungs
(10–12), cochleae of the mammalian ear (13), and the lac-
rimal gland duct and tears (14). It is also a crucial component
of the eye lens, where it is found in particularly high concen-
trations (up to ~200 mg/ml) together with its fellow sHspSubmitted December 30, 2010, and accepted for publication July 25, 2011.
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. Open access under CC BY-NC-ND license.aA-crystallin (15), with which it shares 57% sequence simi-
larity (16). Of interest, aB-crystallin is associated with Ab
deposition in supranuclear cataracts in lenses from patients
with AD (17).
In its native state, aB-crystallin assembles to form a
heterogeneous mixture of oligomers ranging in size from
10 to 40 subunits, with the dominant populations containing
24–33 subunits (18). Each monomeric subunit is a 175
amino acid protein of ~20 kDa in mass and is composed
of an ~90-residue central b-sandwich domain (19), which
is termed the a-crystallin domain and is conserved between
all sHsps (16). The a-crystallin domain is flanked by vari-
able N-terminal and C-terminal regions, with the latter con-
taining an unstructured and highly flexible 12 amino acid
hydrophilic C-terminal extension at its extremity (20,21).
The C-terminal region is important for maintaining the solu-
bility of the protein (21,22) and regulating intersubunit
interactions via the palindromic sequence centered about
the conserved I-X-I motif within the native oligomer (23).
As a result of the latter role, the C-terminal region may
have an important function in chaperone action as regulated
by subunit exchange (24,25). Transmission electron micros-
copy (TEM) shows native aB-crystallin oligomers to be
roughly spherical (26), and cryo-EM reconstructions reveal
a spherical protein shell averaging 13.5 nm in diameter with
an 8.5 nm hollow interior (27,28).
aB-Crystallin is upregulated in response to a multitude of
stress stimuli in vivo and has impressive chaperone abilities
in vitro (21). Interactions of aB-crystallin with many amor-
phously aggregating proteins in vitro have been extensively
documented (29). As an sHsp, it binds to partially foldeddoi: 10.1016/j.bpj.2011.07.056
1682 Shammas et al.proteins in an ATP-independent manner, sequestering them
from aggregation until ATP-dependent chaperones, such as
Hsp-70 and Hsp-90, have an opportunity to restore their
native state (21). aB-Crystallin may also be involved in tar-
geting substrates for degradation, as has been reported for
other members of the sHsp chaperone family (30). Further-
more, aB-crystallin inhibits the growth of amyloid fibrils of
the type found in disease-associated plaques, such as in AD
(reviewed by Ecroyd and Carver (31)).
Amyloid fibrils are highly ordered linear protein aggre-
gates with a cross-b core, typically having widths and
lengths of a few nanometers and micrometers, respectively
(32). Their assembly (from monomer) is a complex process,
and a variety of different species of varying toxicity have
been identified that may be intermediates in the pathway
(33), particularly during the earlier stages of aggregation,
including dimers and small oligomers (34–37), amyloid-
b-derived diffusible ligands (soluble nonfibrillar oligomers)
(38–40), and protofibrils (41,42) (soluble fibril-like oligo-
mers). However, a highly effective model of fibril assembly
can be described by just three kinetic processes: 1), nucle-
ation of fibril seeds from monomeric protein (by unspecified
pathways potentially involving oligomers); 2), elongation of
these structures by incorporation of additional monomers;
and 3), fragmentation of fibrils, which increases the number
of growth sites at the fibril ends and results in exponential
growth kinetics (43,44). Analysis of aggregation kinetics
in terms of these fundamental microscopic processes is
becoming increasingly important for elucidating the molec-
ular basis of aggregate formation and the factors that can
influence its rate, and a variety of methodologies have
been developed to measure the individual processes in isola-
tion (45,46). The lag phase in the growth kinetics can be by-
passed if sufficient concentrations of preformed fibrils (or
seeds) are provided as templates for elongation and subse-
quent fragmentation, resulting in immediate fibril growth
(43). Amyloid fibrils are associated with many degenerative
diseases; however, such fibrils can also be formed from
nondisease-related proteins. The ability to form fibrils is
believed to be a generic property of the polypeptide back-
bone, although the propensity for such formation varies
significantly depending on factors such as the amino acid
sequence and solution conditions (47).
The Ab peptides have a favorable propensity for forming
amyloid fibrils (48). The sequential cleavage of APP by
b- and g-secretases often yields Ab peptides that are 40 or
42 residues long, with the latter isoform having greater
aggregation potential (2). Genetic mutations in the APP-
processing machinery, which increases the level of Ab42
or the ratio of Ab42/Ab40, result in a dramatically earlier
onset of AD (49,50), suggesting an important role for Ab
assembly in the pathogenic cascade. Genetic mutations
within the Ab sequence itself can also reduce the age of
disease onset by increasing the aggregation propensity of
the peptide. One such particularly aggregation-prone AbBiophysical Journal 101(7) 1681–1689peptide is Ab42 with the so-called Arctic mutation
(E22G). This mutation, which was found in a single family
in northern Sweden, gives rise to clinical features of early-
onset AD, reportedly because of a propensity to form proto-
fibrillar species over fibrillar ones (42).
The observation that Ab and aB-crystallin are colocalized
in vivo (3,4) has led to concerted investigations into the effect
of aB-crystallin on Ab aggregation in vitro. A number of
apparently conflicting results have been reported (31), poten-
tially because of differences in the experimental methods
used, including the method of purification and handling of
the Ab peptide, and the incubation conditions. Most studies
indicated that aB-crystallin is capable of inhibiting Ab fibril
formation (51–55), and recent work also showed a protective
effect on Ab-induced cytotoxicity (56). It is important to
consider the mechanism by which aB-crystallin exerts this
protective effect. As previously mentioned, several species
of Ab are present during the aggregation process. Differ-
ences in structure between the various Ab species are likely
to lead to different biophysical properties, such as exposed
hydrophobicity, and as such the interaction between aB-
crystallin and Ab peptides is best examined for each Ab
species in isolation if possible. Investigators have examined
interactions between aB-crystallin and the Ab monomer
using analytical ultracentrifugation, which did not reveal
any complex formation (53). However, NMR studies identi-
fied a weak and transient interaction involving the hydro-
phobic core residues (17–21) of the Ab40 peptide (57).
We recently demonstrated that aB-crystallin binds to
amyloid fibrils formed by a-synuclein, the protein whose
aggregation is linked to Parkinson’s disease, and inhibits
their elongation (58). Given that an interaction between
aB-crystallin and Ab40 fibrils was previously identified
(53), with aB-crystallin preventing the seeded growth of
Ab40 and the nonseeded growth of the Ab42 variant (53),
we decided to study the interaction of these species to inves-
tigate whether fibril binding serves as a generic chaperone
mechanism. We identified the existence of a similar chap-
erone mechanism for preventing aggregation of Ab42 and
its early-onset disease-associated Arctic variant, Ab42arc.
Through the use of fluorescence assays and immunoelectron
microscopy, we found that aB-crystallin binds strongly to
fibrils composed of both Ab42 and Ab42arc peptides. Further-
more, we investigated the mechanistic implications of
this binding interaction directly by studying the effect of
aB-crystallin on the Ab42 amyloid fibril elongation phase
examined in isolation, both in solution using thioflavin T
(ThT) fluorescence, and on a surface using a quartz crystal
microbalance (QCM). We found that aB-crystallin binding
to Ab fibrils strongly inhibits their elongation. Because
the most effective means of extending the lag phase for
amyloid fibril growth is to reduce the elongation (or frag-
mentation) rate (43), this is likely to represent a highly suc-
cessful (and generic) chaperone mechanism for suppressing
fibril proliferation.
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The materials and methods used in this work are described in the Support-
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FIGURE 1 (A) Specificity of binding of aB-crystallin to Ab42 fibrils.
Solutions of 12 mMUCH-L3, GFP, and aB-crystallin in buffer Awere incu-
bated for 1 h at room temperature in the presence and absence of 12 mM
Ab42 fibrils, and then centrifuged for 30 min at 16,000  g. The superna-
tants were separated by SDS-PAGE, and proteins were visualized by stain-
ing with Coomassie-Blue. (B) aB-Crystallin binding to Ab42 fibrils (closed
squares) and Ab42arc fibrils (open circles). aB-Crystallin solutions of
various concentrations were incubated with 15 mM Ab fibrils at room
temperature for 1 h and then centrifuged. The concentration of aB-crystal-
lin in the supernatant was then determined by tryptophan fluorescence as
described in Materials and Methods. The concentration of bound aB-crys-
tallin was calculated as the difference between the estimated total concen-
tration (from the tryptophan fluorescence of an identical solution prepared
without Ab fibrils and centrifugation) and the concentration determined
for the supernatant concentration. The lines represent the line of best fit
to the Scatchard equation for Ab42 (solid line, Vmax ¼ 8.48 5 0.49 mM
corresponding to MMBR ¼ 0.57 5 0.08, K ¼ 2.09 5 0.43 mM) and
Ab42arc (dotted line, Vmax ¼ 5.08 5 0.28 mM corresponding to
MMBR ¼ 0.345 0.03, K ¼ 0.775 0.24 mM).RESULTS
Quantification of aB-crystallin binding
to Ab amyloid fibrils
Initially, we investigated whether aB-crystallin was capable
of binding to Ab42 fibrils using a sedimentation assay. aB-
Crystallin was incubated in the presence of Ab42 fibrils
for 1 h at room temperature, and then the mixture was centri-
fuged under conditions that cause sedimentation of Ab
fibrils but not free aB-crystallin oligomers (Fig. S1).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) analysis (see Fig. 1 A) showed that there was
significantly less aB-crystallin in the supernatant in the
presence of Ab42 fibrils than in its absence, indicating that
aB-crystallin copellets with Ab42 fibrils. That this effect is
not simply nonspecific protein binding was indicated by
the fact that two control proteins of similar mass, i.e., green
fluorescent protein (GFP) and ubiquitin carboxyl-terminal
hydrolase isozyme L3 (UCH-L3), did not copellet under
these conditions (Fig. 1 A). A purely electrostatic effect
was also ruled out, because only a small change in sedimen-
tation behavior was observed when the ionic strength of the
solution was increased (Fig. S2).
To quantify the stoichiometry and affinity of aB-crystallin
binding to Ab fibrils, we performed further sedimentation
experiments over a range of different aB-crystallin concen-
trations (with Ab fibril concentration held constant), and
determined the concentration of aB-crystallin remaining in
the supernatant bymeasuring its intrinsic tryptophan fluores-
cence (Ab has no tryptophan residues). Consistent with the
SDS-PAGE analysis (Fig. 1 A), a highly reproducible reduc-
tion in supernatant fluorescence was observed for aB-crys-
tallin incubated with Ab42 fibrils (Fig. 1 B, black squares).
The concentration of bound aB-crystallin initially increased
with total aB-crystallin concentration, and then reached a
plateau indicating saturation of the available binding sites
(Fig. 1 B, black squares). We analyzed these data using a
single binding-site model with no cooperativity. The satura-
tion isotherm was fitted to Eq. 1 directly (Fig. 1 B, solid
black line, and Supporting Material) to determine both the
dissociation constant for the interaction of 2.1 5 0.4 mM
and the maximum molar binding ratio (MMBR) of 0.575
0.08 aB-crystallin monomers per Ab42 monomer. A similar
analysis was carried out for the binding of aB-crystallin to
fibrils composed of the Ab42arc peptide (Fig. 1 B, red
circles). Again aB-crystallin was observed to copellet with
the fibrils. Upon application of the single binding-site model
(Fig. 1 B, red dotted line), both the dissociation constant and
the MMBR were found to be slightly lower for these fibrils
(0.775 0.24 mM and 0.345 0.03, respectively).Imaging of the Ab fibril complex with aB-crystallin
The high binding ratios reported above suggest that aB-
crystallin binds along the entire length of the fibrils (rather
than being restricted to, e.g., the fibril ends). To investigate
this further, we visualized the fibril-chaperone complex
using immuno-EM. aB-Crystallin was incubated with fibrils
composed of Ab42 and Ab42arc peptides for 1 h at room
temperature. The fibrils were readily observed by negative
staining with uranyl acetate, and showed a morphologyBiophysical Journal 101(7) 1681–1689
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1684 Shammas et al.similar to that typically observed for Ab fibrils (59). By con-
trast, the aB-crystallin oligomer was less readily resolved
(due to its smaller relative size), and therefore samples
were immunolabeled with an antibody directed against
aB-crystallin, which was then stained with a secondary anti-
body conjugated to 10 nm gold nanoparticles. Immunoelec-
tron micrographs of Ab42 and Ab42arc fibrils incubated with
aB-crystallin (Fig. 2, A and C) all show aB-crystallin to be
associated with the fibrils, with gold nanoparticles present
along the entire length of the fibrils, without any apparent
periodicity, and with occasional binding to the ends. Equiv-
alent control samples incubated without aB-crystallin are
shown in Fig. 2, B and D. No nonspecific immunolabeling
was observed. Similar experiments with fibrils composed
of Ab40 peptide showed the same behavior (Fig. S3).FIGURE 3 Inhibition of Ab fibril elongation by aB-crystallin binding.
Ab fibril elongation kinetics for Ab42 (A) and Ab42arc (B) fibrils (fAb) at
room temperature in buffer A in the presence and absence of aB-crystallin.
The solutions examined were LMWAb alone (black squares), LMW Ab
with fibril seed (red circles), LMWAb with fibril seed and a low concentra-
tion of aB-crystallin (green triangles), and LMW Ab with aB-crystallin
bound to fibril seeds (blue triangles). The fluorescence traces plotted are
the average of three replicates and are reported relative to the starting fluo-
rescence of solutions containing Ab fibrils but no aB-crystallin. Control
solutions of LMW Ab with aB-crystallin displayed behavior similar to
that observed for LMWAb alone. Solutions containing aB-crystallin and
ThT alone showed no change in fluorescence over these timescales. (C)
The initial elongation rates for Ab42 (black bars) and Ab42arc (white
bars) were determined from the gradient of the linear fit to the first portion
of data (1000 s for Ab42, 200 s for Ab42arc) for three repeats. Initial rates
have been normalized with respect to Ab elongation in the presence ofaB-Crystallin-mediated inhibition
of Ab fibril elongation
The binding of aB-crystallin inhibits the aggregation of
a-synuclein in solution (60,61), and it was recently shown
that binding to a-synuclein fibrils specifically and dramati-
cally reduces the rate of fibril elongation (58). Given pre-
vious reports that aB-crystallin inhibits Ab aggregation in
solution (31), we investigated whether aB-crystallin binding
to Ab fibrils also directly inhibits fibril growth, using in situ
ThT measurements of seeded growth (Fig. 3). In the absence
of aB-crystallin, efficient seeding of fibril growth from both
Ab42 and Ab42arc fibrils was observed (Fig. 3, red circles).
Ab fibrils were incubated in the presence of aB-crystallin
(at a molar ratio of 2:1) for 1 h at room temperature to allow
saturation of aB-crystallin binding to the fibrils. We then
tested these fibrils for their seeding ability by introducing
them into a solution of low-molecular-weight (LMW) AbFIGURE 2 Immuno-EM of Ab42 and Ab42arc fibrils in the presence
(A and C) and absence (B and D) of aB-crystallin, respectively. All scale
bars represent 200 nm. Ab fibrils were prepared and incubated in the pres-
ence or absence of an equal molar concentration of aB-crystallin for 1 h at
room temperature. The mixtures were centrifuged at 16,000 g for 30 min,
and the pellets were resuspended and treated as described in Materials and
Methods. Similar images were observed for Ab40 fibrils (Fig. S2).
Ab seeds and the absence of aB-crystallin. Reported rates are the mean
and standard deviation of the three repeats. The fibril seeds were preincu-
bated with aB-crystallin for 1 h at room temperature. Concentrations of
Ab fibrils and aB-crystallin (when present) were ~0.8 mM and 0.4 mM,
respectively. Concentrations of LMW Ab were 9.7 mM and 1.8 mM for
Ab42 and Ab42arc, respectively.
Biophysical Journal 101(7) 1681–1689(see Supporting Material) and monitoring fibril growth via
ThT fluorescence. Fibril seeds that were preincubated with
an equivalent concentration of aB-crystallin were com-
pletely unable to seed further Ab fibril elongation. More-
over, the ThT fluorescence of the seed fibrils was
unchanged in the presence of aB-crystallin, as judged by
the fluorescence intensity at time zero (Fig. 3, A and B),
indicating that the chaperone did not disaggregate the seeds.
Upon addition of aB-crystallin (to a final concentration of
0.4 mM) to seeded Ab42, a significant decrease in the elon-
gation rate was only observed after ~30 min (Fig. 3 A).
Together, these findings implicate a slow binding of the
chaperone to the fibril seeds as the origin of this inhibition.
It is interesting that without preincubation of Ab42 fibril
Binding of aB-Crystallin to Ab Fibrils 1685seeds with the chaperone, inhibition of seeded growth
occurred after ~30 min after the addition of aB-crystallin
(Fig. 3 A), which may correspond to the time required for
aB-crystallin to bind to the fibrils in its active form. By
contrast, for Ab42arc, which aggregates much faster than
Ab42 (over ~10 min, compared with ~2 h), strong inhibition
was observed only when the fibril seeds were preincubated
with the chaperone (Fig. 3 B).
We also examined the inhibition of Ab fibril growth using
a QCM. In previous applications of this technique, we
showed that when preformed seed fibrils are attached to
the surface of the quartz crystal, this kinetic assay is highly
specific for the elongation step of the overall fibrillization
pathway (45,58,62,63). Ab42 fibrils were covalently
attached to the surface of the sensor crystal as previously
described (63). Their rate of elongation was then observed
as a change in the resonant frequency of the quartz sensor,
which reflects an increase in the surface-bound mass (see
Materials and Methods for details). A QCM sensor crystal
covered with Ab42 fibril seeds was exposed to solutions of
LMW Ab42 and aB-crystallin. Exposure of QCM sensors
with no attached seeds to LMW Ab does not result in a
significant change in the resonant frequency of the system
(63). In contrast, exposure of QCM sensors covered with
Ab42 fibril seeds to LMW Ab42 yielded a linear decrease
in resonant frequency over the course of several minutes,
corresponding to a steady rate of fibril elongation (seeA B
DCFig. 3 A). The introduction of 2.5 mM aB-crystallin caused
a decrease in frequency that showed a different kinetic
profile, namely, a saturable attachment of the chaperone to
the surface (Fig. 4 A). Nonspecific adsorption of aB-crystal-
lin was also observed for QCM sensors without attached
fibril seeds; however, the observed increase in mass was
less extensive than that found in the presence of bound seeds
(Fig. S4 B). Once the fibrils had been exposed to aB-crystal-
lin, they lost the ability to support further Ab monomer
deposition, when probed by renewed incubation of the
sensor surface with Ab42 solution (Fig. 4, A and B). Control
experiments demonstrated that renewed incubation of the
surface-bound seeds with LMW Ab resulted in additional
fibril elongation if there was no intermittent contact with
aB-crystallin (Fig. S4 A). Because the chaperone and Ab
solutions were added sequentially with an intervening buffer
wash of the liquid cell, the deactivation of fibril growth sites
by chaperone binding, rather than the sequestration of amy-
loidogenic species in solution, must be responsible for the
observed inhibition of increasing mass. After the QCM
experiments, we acquired atomic force microscopy images
of the functionalized sensors using tapping mode in air,
and observed that the fibrils had lengthened (Fig. 4, C and
D). Finally, we investigated the reversibility of the inhibition
by allowing the aB-crystallin to dissociate from the fibril
seeds by washing with a 3 M solution of the denaturant
guanidinium chloride (this concentration was shown not toFIGURE 4 (A) Inhibition of Ab42 fibril elonga-
tion by aB-crystallin probed by QCM. A decrease
in resonant frequency (overtone with N¼ 3 shown)
indicates attachment of protein. At 38C, Ab fibrils
were incubated in buffer C (100 mM phosphate,
pH 7.4) before injection of 1.7 mM LMW Ab42.
Buffer C then replaced the Ab42 solution, quench-
ing amyloid fibril elongation. After incubations
with 2.5 mM aB-crystallin, the Ab42 fibril chip
was again exposed to a solution of 1.7 mM LMW
Ab42, which did not lead to a frequency shift com-
parable to that observed during the first incubation
with LMW Ab42, demonstrating the inhibitory
effect of aB-crystallin. (B) The rate of frequency
drop for the two periods of Ab42 exposure deter-
mined from straight line fitting. The error bars
represent the largest variation between the overall
rate and local rates during the second exposure.
AFM images of typical QCM sensor surfaces
before (C) and after (D) exposure to Ab solutions
demonstrate fibril elongation.
Biophysical Journal 101(7) 1681–1689
1686 Shammas et al.dissolve Ab fibrils; data not shown). Subsequently, these
seeds were able to elongate again when exposed to LMW
Ab42 (Fig S4 C).DISCUSSION
Amyloid fibrils are not simply inert products of protein
aggregation; rather, they are dynamic species that have the
ability not only to grow but also to fragment and dissociate
(43,64). Given the association of aB-crystallin (7,24) and
other sHsps with Ab plaques in AD, we investigated
whether this archetypical sHsp chaperone has the ability
to influence one of the crucial stages of fibril formation,
the elongation phase of amyloid growth. We demonstrated
in this study that aB-crystallin selectively binds to Ab42
and Ab42arc fibrils with micromolar affinity, with high
MMBRs for aB-crystallin (Ab ¼ 0.575 0.08 and 0.345
0.03, respectively). These values are highly consistent with
immuno-EM data showing that the chaperone molecules
bind along the length and at the ends of the fibrils. A previ-
ously described simple geometric model (58) indicated
values of 0.2–0.7 for maximum coverage of the fibril. To
elucidate the consequences of this interaction, we performed
investigations into the effects of aB-crystallin on seeded Ab
fibril growth, both in solution and on the surface of a QCM
biosensor. We observed that while bound, aB-crystallin
strongly retards the rate of fibril elongation (Figs. 3 and 4),
and that once it is removed, fibril elongation can be resumed
(Fig. S4 C). The significant difference in seeding efficiency
between fibrils with bound aB-crystallin and fibrils with
unbound aB-crystallin (Fig. 3) demonstrates that aB-crys-
tallin binding to fibrils can directly inhibit fibril growth.
This result is inconsistent with inhibition due to chaperone
binding to Abmonomer or early oligomers, because a larger
concentration of aB-crystallin is available for binding these
species in the latter case, where no inhibition is observed.
The process of protein aggregation and amyloid forma-
tion is characterized by sigmoidal assembly kinetics, with
a lag phase before rapid growth. The duration of the lag
phase is usually shown to be heavily dominated by the rates
of elongation and fragmentation while varying only loga-
rithmically with the nucleation rate (43). With such a
scenario, the most effective way to extend the lag phase
would be to reduce the elongation or fragmentation rate,
not the nucleation rate. Hence, the binding of a chaperone
to fibrils to inhibit their further elongation, as observed
here, is very likely to be critical and highly influential mech-
anistically, in terms of an effective inhibitory activity of the
chaperone. Binding along the fibril length (l) may appear to
be a fairly inefficient mechanism for inhibiting fibril elonga-
tion, because for a cylinder of radius r, only a proportion
r/(rþl) of the area is at the ends. In the initial stages of
aggregation, the fibrils/fibril precursors are much shorter,
making it more efficient than in the case of mature fibrils.
For example, for fibrils of radius 2–5 nm (as suggested byBiophysical Journal 101(7) 1681–1689AFM images) and short fibrils of ~20 nm, these calculations
suggest ratios of 11:1 to 5:1. In addition, binding of the sHsp
to the fibril could also serve additional roles, such as
coverage of potentially toxic fibril surfaces (65), affecting
fibril fragmentation rates, or targeting the fibrils for degrada-
tion (30).
We recently showed, using immunogold labeling TEM,
that aB-crystallin can also bind to amyloid fibrils formed
from an alternative target protein, a-synuclein (58). The
binding interaction suppressed a-synuclein fibril elongation
in a manner analogous to that found here for aB-crystallin
with Ab amyloid fibrils. This anti-aggregation activity of
aB-crystallin toward the elongation phase of amyloid
assembly could be a general mechanistic phenomenon in-
volving sHsps and many or all amyloid fibrils. This conclu-
sion is further supported by the observation from QCM
studies that aB-crystallin inhibits the elongation of insulin
amyloid fibrils (45).
It is interesting that fibrils formed from two different Ab
peptides showed similar MMBR values for aB-crystallin
binding, despite significant differences in their capacity to
bind ThT (data not shown). They are also comparable to
the approximate MBR determined from a-synuclein fibrils
(58), which may represent further evidence for a common
mechanism of binding of aB-crystallin to amyloid fibrils.
The fact that the measured ThT fluorescence of the fibril
seeds is not diminished by the addition of aB-crystallin
(Fig. 3) suggests that the mechanism and/or region of chap-
erone binding is distinct from that of the ThT dye. aB-Crys-
tallin binds target proteins in part via exposed regions of
hydrophobicity (21,31,66); hence, it is possible that aB-
crystallin binds to amyloid fibrils through association with
hydrophobic regions of the Ab peptides or a-synuclein
that protrude from the main cross-b amyloid fibril core.
Assuming that the chaperone activity of aB-crystallin is
in part mediated by its ability to bind to patches of exposed
hydrophobicity on aggregation-prone target proteins
(21,31,66), it is likely that this sHsp associates with addi-
tional species on the amyloid formation pathway that also
have exposed hydrophobic regions. Indeed, a weak and tran-
sient interaction was previously proposed for aB-crystallin
with Abmonomers (57). Consistent with this, the interaction
of aB-crystallin with species early along the a-synuclein
fibril-forming pathway has been well characterized (60,61).
Typically, sHsps (including aB-crystallin (31)) are local-
ized inside cells as cytoplasmic proteins, although there
have been reports of extracellular sHsps (67). The associa-
tion of aB-crystallin with Ab peptides in AD plaques, which
are extracellular, may therefore be a result of their release
from cells after damage associated with Ab oligomers,
which are proposed to be the primary neurotoxic species.
Of interest, Friedrich et al. (68) recently showed that in
cell culture, Ab plaque formation occurs intracellularly
and leads to cell death before the plaques are released into
the extracellular space. Thus, because of the significant
Binding of aB-Crystallin to Ab Fibrils 1687intracellular phase of Ab aggregation, there may be ample
opportunity for Ab to interact with aB-crystallin and other
sHsps. A number of studies have suggested that aB-crystal-
lin can influence amyloid fibril assembly via interactions
with early-stage fibrillar oligomers. For example, it has
been shown that aB-crystallin can redirect the amyloido-
genic a-synuclein protein toward an amorphous aggregation
pathway with more easily degradable end products (60).
One study indicated that aB-crystallin not only inhibits
amyloid fibril formation by the Ab peptides but also pro-
motes the formation of alternative stable structures that
are more toxic to cells (52). However, a more recent study
showed that aB-crystallin inhibits amyloid fibril formation
and its associated cell toxicity for both k-casein and Ab40
peptides (56). aB-Crystallin is much more efficient at
inhibiting slowly aggregating target proteins along the
amorphous (69) and fibril-forming (61,70–72) pathways.
Consistent with this finding, we observed that because of
its slower aggregation rate, Ab42 enabled aB-crystallin to
interact with its fibrils to partially inhibit fibril growth
(Fig. 3 A), whereas LMW Ab42arc and fAb42arc did not
(Fig. 3 B). Further investigations into the specific mecha-
nistic processes involved in the interaction between aB-
crystallin and isolated oligomeric Ab amyloid intermediates
will therefore be of interest.
It is interesting to speculate about the physiological implica-
tions of the interactions between aB-crystallin and elongating
fibrils described here, and the influence these processes may
have on their links with disease. As described earlier, the elon-
gation phase is critical for determining the overall kinetics of
the process of amyloid assembly (43), and hence a chaperone
that is capable of inhibiting this stage of amyloid growth is
likely to be a powerful suppressor of fibril proliferation.
Further, the ability of aB-crystallin to bind fibrils with micro-
molar affinity is interesting inview of recent reports that sHsps
are able not only to inhibit aggregation but also to target
substrates for degradation (30). It is therefore possible that
this binding interaction could be valuable for promoting the
disposal of amyloidogenic species in vivo.CONCLUSIONS
In summary, the data presented here reveal that aB-crystal-
lin binds to Ab amyloid fibrils, and through this interaction
suppresses the elongation phase of Ab42 fibril growth in
a highly effective manner. Given the increasing number of
amyloid fibril systems in which this behavior has now
been observed (e.g., Ab40, Ab42, Ab42arc, a-synuclein, and
insulin), this activity appears to be a generic function of
this archetypical sHsp, whereby it displays chaperone
behavior toward all amyloid fibrils regardless of their
constituent target proteins. Overall, therefore, it is likely
that all species along the amyloid fibril-forming pathway,
including oligomers and fibrils, will interact with molecular
chaperones, such as sHsps, because all are misfolded andpotentially expose hydrophobic regions. This process may
offer a more comprehensive protection against the toxicity
associated with amyloid fibrils than that obtained from inter-
action with the monomeric or oligomeric species only.SUPPORTING MATERIAL
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